LEXXNasdaqPharmaceutical Preparations

Lexaria Bioscience Corp. (LEXX) earnings date, market-implied expected move, and options open interest by expiry

4.12

+0.09 · +2.23%

Regular session13:04 ET

Open4.15Volume32,034Mkt cap$6.7M

Day4.05 – 4.3028%52-wk2.43 – 21.609%

LEXX

Lexaria Bioscience Corp.

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

No implied move.

Expected move

Inputs

Next report

Nov 20

in 16 days

est.Q4 FY26

Calendar

Next report

Last report

—

Largest filed tie

—

13F top-10 QoQ

+7.60%

shares held · 10 largest managers

13F · Jun 30 '26127d lag

26 managers

Top fund weight

—

Lexaria Bioscience (LEXX) is expected to report on Nov 20 (estimated date).

Implied vs realized

No reported quarters.

Implied vs realized

Positioning

No open-interest data.

Positioning

Linked exposure

No linked exposure.

Linked exposure

Revenue flow

as filedQ2 FY26

−7263.66%as filednet margin · revenue −88.51% YoY

Revenue$20,000—

Gross profit$20,000100.00%—

Operating income−$1M−7259.52%+7.74%

Pre-tax income−$1M+9.12%

Net income−$1M−7263.66%+9.06%

Cost of revenue$0—

Operating expenses$1M−6.46%

Tax$2,598+45.06%

Other income$1,769+108.01%

Source: SEC filings · standardized · QE Feb 28 '26 · bars = % of revenue

Revenue flow

Intraday

15m bars

Hatch = extended hours · ▯ up · ▮ downSource: market data · 13:00 ET

Intraday

Event sensitivity

PPI ×1.93· ±9.4% vs ±4.9% · 10 releases

eventrelease day|move|up · n×base

PPIproducer prices±9.4%6 of 10×1.93

NFPjobs report±5.7%4 of 10×1.16

FOMCrate decision±5.6%15 of 24×1.16

PCEpersonal income & outlays±5.0%4 of 19×1.03

GDPgross domestic product±3.7%10 of 19×0.76

CPROFcorporate profits±3.0%6 of 12×0.62

CPIconsumer prices±2.4%5 of 10×0.50

Bar = avg |move| to ±10% · tick = ±4.9% avg day · ×base = |move| ÷ ±4.9% · min 6 releases

Earnings history

EPS -0.08 · consensus —

Quarter	Reported	EPS	Consensus
Q3 FY26	—	-0.08	—
Q2 FY26	—	-0.06	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod